Newer classes of anti-myeloma agents approved in recent years, including selinexor (an inhibitor of exportin 1), Teclistamab (BCMA-redirected bispecific T cell engager), and belantamab mafodotin (an antibody-drug conjugate targeting BCMA), have reported median PFS between 3.7 to 11.3 months [12–14]. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.